DailyMed: Wegovy prescribing information
Source of approved indication scope for semaglutide under this brand context.
Reference library
References
FDA, DailyMed, ClinicalTrials.gov, PubMed, peer-reviewed, and clearly labeled sponsor sources used by the Watchlist.
Source inclusion does not imply endorsement. Regulatory and label sources define product status and boundaries; sponsor releases are tracking inputs; clinical claims still depend on the specific population, product, endpoint, and study design.
DailyMed: Zepbound prescribing information
Source of approved indication scope for tirzepatide under this brand context.
DailyMed: Egrifta WR prescribing information
Source of approved indication scope for tesamorelin in HIV-associated lipodystrophy.
DailyMed: Sirolimus prescribing information
Used to distinguish approved sirolimus contexts from longevity claims.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
Peer-reviewed phase 2 obesity trial; endpoint interpretation remains indication-specific.
ClinicalTrials.gov: Retatrutide TRIUMPH-8 study record
Late-stage study record used to track phase and trial status, not efficacy claims.
Interim results from the phase 2 COURAGE trial
Sponsor-released interim data; should be separated from peer-reviewed outcomes.
Certain bulk drug substances for use in compounding that may present significant safety risks
Regulatory source for compounding-safety watch items; status should be rechecked before publication.
Bulk drug substances used in compounding
General FDA framework for compounding from bulk drug substances.
GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
Mechanistic and skin-regeneration review; not proof of broad systemic claims.
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
Human cosmetic-dermatology context; does not validate systemic wellness claims.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Highlights public interest and need for controlled human trials.
Research advances on thymosin beta-4 in promoting wound healing
Thymosin beta-4 review; internet TB-500 claims may not match studied products.
Thymosin beta-4: A potential novel adjunct treatment for bacterial keratitis
Ophthalmology-focused context; not support for broad recovery claims.
Mitochondrial-derived peptides and metabolic states: systematic review and meta-analysis
Association and mechanistic literature; clinical-outcome translation remains unsettled.
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295
Early human endocrine signal; not a broad wellness outcome trial.
Proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus
Specific investigational context; not evidence for anti-aging or body-composition claims.
FDA briefing material discussing AOD-9604 evidence
Regulatory review material; used for caution around identity, evidence, and compounding status.
Evaluation of LL-37 in hard-to-heal venous leg ulcers
Specific topical wound context; does not validate broad antimicrobial self-use claims.
Antimicrobial and cytotoxicity evaluation of LL-37 analogs
Preclinical safety-relevant signal for native LL-37 and analog development.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Preclinical/mechanistic anti-inflammatory context.
Safety and metabolism of long-term nicotinamide riboside in healthy overweight adults
Human NAD-biomarker and safety context; not proof of longevity outcomes.
NMN supplementation in healthy middle-aged adults: randomized multicenter trial
Human biomarker and function signals; outcome generalization should be conservative.
NMN increased blood NAD levels in older adults in a randomized study
Biomarker movement with selected functional secondary outcomes.
Topical rapamycin reduces markers of senescence and aging in human skin
Exploratory tissue-specific human study; not systemic lifespan evidence.
Repetitive transcranial magnetic stimulation systems: special controls guidance
Device regulatory framework and risk controls.
Brain stimulation therapies
Patient-facing overview of FDA-cleared rTMS contexts.
Psilocybin treatment for major depressive disorder: randomized clinical trial
Randomized study with structured psychological support; investigational, not FDA-approved.
Trial of psilocybin versus escitalopram for depression
Controlled depression trial; interpretation depends on design and support model.
Ibogaine: therapeutic potential, cardiac safety, and translational perspectives
Safety-focused review emphasizing need for rigorous clinical pathways.
Ibogaine consumption with QTc prolongation and captured cardiac dysrhythmias
Safety case report relevant to cardiac risk boundary.
DailyMed: Spravato prescribing information
Used for ketamine/esketamine queue context; not a general endorsement of off-label ketamine claims.
No references match the current filters.